Dose-dependent impact of tixagevimab–cilgavimab as primary prevention against SARS-CoV-2 in immunocompromised individuals

D Daniela Dluzynski P Paddy Ssentongo C Cory M. Hale S Shareef K. Shaheen N Natella Maglakelidze J Jeffrey M. Sivik M Maria Paula Henao V Vernon M. Chinchilli C Catharine I. Paules

Article Details

Volume / Issue Vol. 15, Issue 1
Published May 21, 2025
ISSN 2045-2322
Publisher Nature Portfolio

Journal Info

Scientific Reports

Nature Portfolio

ISSN: 2045-2322 Open Access Life Sciences

Authors (9)

D

Daniela Dluzynski

P

Paddy Ssentongo

C

Cory M. Hale

S

Shareef K. Shaheen

N

Natella Maglakelidze

J

Jeffrey M. Sivik

M

Maria Paula Henao

V

Vernon M. Chinchilli

C

Catharine I. Paules